Results 111 to 120 of about 20,369 (147)

Clinical Application of Pharmacogenomics in Stroke Management: Current Evidence and Future Directions. [PDF]

J Stroke
Lee KJ, Kang M, Lee EJ, Oh J, Han NY, Lee JY, Lee JY, Lee SJ, Debette S, Paré G, Woo D, Eldeiry A, Kim YS, Kim J, Park JM, Lee J, Sung J, Choi JC, Bae HJ.   +18 more
europepmc   +1 more source

Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders. [PDF]

Front Pharmacol
Chenchula S, Shubham A, Abhijit R, Modak T, Komal K, Jhaj R, Jitendra S, V S, Balakrishnan S.   +8 more
europepmc   +1 more source

Effect of insulin resistance on ticagrelor-versus clopidogrel-based dual antiplatelet therapy for secondary prevention of stroke in carriers of <i>CYP2C19</i> loss-of-function mutations. [PDF]

CMAJ
Zhao J, Tian X, Yang X, Xu Q, Xia X, Zhang Y, Xie X, Bath PM, Jing J, Wang Y, Meng X, Wang A.   +11 more
europepmc   +1 more source

Toward a More accurate, Evidence-Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems. [PDF]

Clin Pharmacol Ther
Backman JT.
europepmc   +1 more source

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications. [PDF]

Clin Transl Sci
Schmith VD, Graden D, Lohmer LLR, Schleyer J, Wanaski SP.   +4 more
europepmc   +1 more source

Comprehensive Molecular Evaluation of Transcription Factor 7-like 2, Long Noncoding RNA (ANRIL), and CYP2C19*17 Gene Variants and Their Association with Predisposition and Progression in Stroke Patients. [PDF]

Cell Mol Neurobiol
Hamadi A, Mir R, Al-Amer OM, Alasseiri M, Elfaki I, Alanazi MA, Moawadh MS, Barnawi J, Oyouni AAA, Hamdi RI, Alharbi KI.   +10 more
europepmc   +1 more source

Multi-omics analysis of key lipid metabolism-related genes involved in the anti-hepatocellular carcinoma effect of dihydroartemisinin. [PDF]

Discov Oncol
Guo J, Li L, Chen Y, Gao J, Xie Y, Li Q, Zhang Z.   +6 more
europepmc   +1 more source

Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses. [PDF]

Front Pharmacol
Jiang Z, Qu X, Yan Z, Fang J, Lan J, Zhao X, Qi W.   +6 more
europepmc   +1 more source